Our MissionOur Mission is to Reduce the Incidence
of Late Stage Cancer by 50% Over the Next Decade through Early Cancer Detection |
Our Story
|
StageZero Life Sciences (TSX-SZLS) is dedicated to the early detection of cancer and multiple disease states through whole blood. Our next-generation test, Aristotle®, is a panel for simultaneously screening for 10 cancers from a single blood sample. Aristotle has been built on the company's mRNA Sentinel Principle Technology Platform, which was used to develop one of the first commercially available blood tests for Colorectal Cancer, ColonSentry®.
|
|
Pioneers in Liquid Biopsy
As early pioneers in liquid biopsies, we developed one of the first blood-based biomarker tests for the early identification of Colorectal Cancer. ColonSentry® uses our proprietary Sentinel Principle technology which is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. Today, more than 100,000 patients in the U.S. have benefited from the ColonSentry test. |
The Next Generation Test for Cancer
Our next generation test, Aristotle, uses proven technology to test for ten cancers from a single blood sample. Aristotle has high sensitivity and specificity across multiple cancers. In addition to cancer Aristotle has the ability to test for multiple disease states including Psychiatric Disorders, Heart Disease and Autoimmune Disorders. |
Our Clinical Reference Laboratory
Our CLIA certified and CAP accredited clinical reference lab based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. Our goal is to provide the best cancer risk assessment tests that are available today for early cancer risk assessment.
